$1 Trial Offer - Realtime Screener -- Try out our Realtime Product, GetStockIdeas. The advanced screener tool is a momentum trader's dream!

GW Pharmaceuticals PLC Sponsored ADR
(NASDAQ : GWPH)

( )
GWPH PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Loading GWPH News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
1.80%31.098.8%$1056.06m
PRGOPerrigo Co. Plc
0.72%88.484.2%$226.01m
SHPGShire PLC Sponsored ADR
-1.13%191.670.4%$182.66m
ENDPEndo International Plc
-4.80%21.036.0%$174.24m
MNKMallinckrodt Plc
-4.97%75.218.3%$151.26m
JAZZJazz Pharmaceuticals Plc
-2.00%127.362.5%$103.03m
HZNPHorizon Pharma plc
-4.53%19.1811.8%$93.67m
RLYPRelypsa, Inc.
0.00%31.9620.9%$76.90m
UTHRUnited Therapeutics Corporation
-1.27%123.2620.2%$66.00m
ICPTIntercept Pharmaceuticals, Inc.
-3.02%153.6417.6%$60.01m
ALRAlere Inc.
0.22%40.713.7%$51.79m
PTLAPortola Pharmaceuticals, Inc.
-2.99%19.805.5%$36.04m
ICLRICON Plc
0.04%75.053.6%$31.49m
PCRXPacira Pharmaceuticals, Inc.
-0.65%39.6013.0%$30.45m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.20%81.548.4%$29.79m

Company Profile

GW Pharmaceuticals Plc engages in the business of discovering, developing and commercializing novel therapeutics from proprietary cannabinoid product platform in a broad range of disease areas. The company operates through the following segments: Commercial, Sativex Research & Development and Pipeline Research & Development. The Commercial segment promotes Sativex through strategic collaborations with major pharmaceutical companies for the currently approved indication of spasticity due to multiple sclerosis. The Sativex Research & Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research & Development segment seeks to develop cannabinoid medications other than Sativex, which are using the Group's proprietary cannabinoid technology platform. GW Pharmaceuticals was founded by Geoffrey W. Guy and Brian Whittle in 1998 and is headquartered in Salisbury, the United Kingdom.